Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor

Chaim O. Jacob, Ning Yu, Shunhua Guo, Noam Jacob, William J. Quinn, Vishal Sindhava, Michael P. Cancro, Beatrice Goilav, Chaim Putterman, Thi Sau Migone, William Stohl

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective To determine the necessity for any individual BAFF receptor in the development of systemic lupus erythematosus (SLE). Methods Bcma-, Taci-, and Br3-null mutations were introgressed into NZM 2328 mice. NZM.Bcma -/-, NZM.Taci-/-, and NZM.Br3-/- mice were evaluated for lymphocyte phenotype and BAFF receptor expression by flow cytometry; for B cell responsiveness to BAFF by in vitro culture; for serum levels of BAFF and total IgG and IgG anti-double-stranded DNA (anti-dsDNA) by enzyme-linked immunosorbent assay; for renal immunopathology by immunofluorescence and histopathology; and for clinical disease. Results BCMA, TACI, and B lymphocyte stimulator receptor 3 (BR3) were not surface-expressed in NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice, respectively. Transitional and follicular B cells from NZM.Br3-/- mice were much less responsive to BAFF than were the corresponding cells from wild-type, NZM.Bcma-/-, or NZM.Taci-/- mice. In comparison with wild-type mice, NZM.Bcma-/- and NZM.Taci-/- mice harbored an increased number of spleen B cells, T cells, and plasma cells, whereas serum levels of total IgG and IgG anti-dsDNA were similar to those in wild-type mice. Despite their paucity of B cells, NZM.Br3-/- mice had an increased number of T cells, and the numbers of plasma cells and levels of IgG anti-dsDNA were similar to those in wild-type mice. Serum levels of BAFF were increased in NZM.Taci-/- and NZM.Br3-/- mice but were decreased in NZM.Bcma-/- mice. Despite their phenotypic differences, NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice had renal immunopathology and clinical disease that were at least as severe as that in wild-type mice. Conclusion Any single BAFF receptor, including BR3, is dispensable for the development of SLE in NZM mice. Development of disease in NZM.Br3-/- mice demonstrates that BAFF-BCMA and/or BAFF-TACI interactions contribute to SLE, and that a profound, life-long reduction in the numbers of B cells does not guarantee protection against SLE.

Original languageEnglish (US)
Pages (from-to)1043-1054
Number of pages12
JournalArthritis and Rheumatism
Volume65
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

B-Cell Activation Factor Receptor
Systemic Lupus Erythematosus
B-Lymphocytes
Plasma Cells
Immunoglobulin G
Serum
B-Cell Activating Factor

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Jacob, C. O., Yu, N., Guo, S., Jacob, N., Quinn, W. J., Sindhava, V., ... Stohl, W. (2013). Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis and Rheumatism, 65(4), 1043-1054. https://doi.org/10.1002/art.37846

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. / Jacob, Chaim O.; Yu, Ning; Guo, Shunhua; Jacob, Noam; Quinn, William J.; Sindhava, Vishal; Cancro, Michael P.; Goilav, Beatrice; Putterman, Chaim; Migone, Thi Sau; Stohl, William.

In: Arthritis and Rheumatism, Vol. 65, No. 4, 04.2013, p. 1043-1054.

Research output: Contribution to journalArticle

Jacob, CO, Yu, N, Guo, S, Jacob, N, Quinn, WJ, Sindhava, V, Cancro, MP, Goilav, B, Putterman, C, Migone, TS & Stohl, W 2013, 'Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor', Arthritis and Rheumatism, vol. 65, no. 4, pp. 1043-1054. https://doi.org/10.1002/art.37846
Jacob, Chaim O. ; Yu, Ning ; Guo, Shunhua ; Jacob, Noam ; Quinn, William J. ; Sindhava, Vishal ; Cancro, Michael P. ; Goilav, Beatrice ; Putterman, Chaim ; Migone, Thi Sau ; Stohl, William. / Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. In: Arthritis and Rheumatism. 2013 ; Vol. 65, No. 4. pp. 1043-1054.
@article{98a2651108ee440cb99999e941f9ff8f,
title = "Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor",
abstract = "Objective To determine the necessity for any individual BAFF receptor in the development of systemic lupus erythematosus (SLE). Methods Bcma-, Taci-, and Br3-null mutations were introgressed into NZM 2328 mice. NZM.Bcma -/-, NZM.Taci-/-, and NZM.Br3-/- mice were evaluated for lymphocyte phenotype and BAFF receptor expression by flow cytometry; for B cell responsiveness to BAFF by in vitro culture; for serum levels of BAFF and total IgG and IgG anti-double-stranded DNA (anti-dsDNA) by enzyme-linked immunosorbent assay; for renal immunopathology by immunofluorescence and histopathology; and for clinical disease. Results BCMA, TACI, and B lymphocyte stimulator receptor 3 (BR3) were not surface-expressed in NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice, respectively. Transitional and follicular B cells from NZM.Br3-/- mice were much less responsive to BAFF than were the corresponding cells from wild-type, NZM.Bcma-/-, or NZM.Taci-/- mice. In comparison with wild-type mice, NZM.Bcma-/- and NZM.Taci-/- mice harbored an increased number of spleen B cells, T cells, and plasma cells, whereas serum levels of total IgG and IgG anti-dsDNA were similar to those in wild-type mice. Despite their paucity of B cells, NZM.Br3-/- mice had an increased number of T cells, and the numbers of plasma cells and levels of IgG anti-dsDNA were similar to those in wild-type mice. Serum levels of BAFF were increased in NZM.Taci-/- and NZM.Br3-/- mice but were decreased in NZM.Bcma-/- mice. Despite their phenotypic differences, NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice had renal immunopathology and clinical disease that were at least as severe as that in wild-type mice. Conclusion Any single BAFF receptor, including BR3, is dispensable for the development of SLE in NZM mice. Development of disease in NZM.Br3-/- mice demonstrates that BAFF-BCMA and/or BAFF-TACI interactions contribute to SLE, and that a profound, life-long reduction in the numbers of B cells does not guarantee protection against SLE.",
author = "Jacob, {Chaim O.} and Ning Yu and Shunhua Guo and Noam Jacob and Quinn, {William J.} and Vishal Sindhava and Cancro, {Michael P.} and Beatrice Goilav and Chaim Putterman and Migone, {Thi Sau} and William Stohl",
year = "2013",
month = "4",
doi = "10.1002/art.37846",
language = "English (US)",
volume = "65",
pages = "1043--1054",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor

AU - Jacob, Chaim O.

AU - Yu, Ning

AU - Guo, Shunhua

AU - Jacob, Noam

AU - Quinn, William J.

AU - Sindhava, Vishal

AU - Cancro, Michael P.

AU - Goilav, Beatrice

AU - Putterman, Chaim

AU - Migone, Thi Sau

AU - Stohl, William

PY - 2013/4

Y1 - 2013/4

N2 - Objective To determine the necessity for any individual BAFF receptor in the development of systemic lupus erythematosus (SLE). Methods Bcma-, Taci-, and Br3-null mutations were introgressed into NZM 2328 mice. NZM.Bcma -/-, NZM.Taci-/-, and NZM.Br3-/- mice were evaluated for lymphocyte phenotype and BAFF receptor expression by flow cytometry; for B cell responsiveness to BAFF by in vitro culture; for serum levels of BAFF and total IgG and IgG anti-double-stranded DNA (anti-dsDNA) by enzyme-linked immunosorbent assay; for renal immunopathology by immunofluorescence and histopathology; and for clinical disease. Results BCMA, TACI, and B lymphocyte stimulator receptor 3 (BR3) were not surface-expressed in NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice, respectively. Transitional and follicular B cells from NZM.Br3-/- mice were much less responsive to BAFF than were the corresponding cells from wild-type, NZM.Bcma-/-, or NZM.Taci-/- mice. In comparison with wild-type mice, NZM.Bcma-/- and NZM.Taci-/- mice harbored an increased number of spleen B cells, T cells, and plasma cells, whereas serum levels of total IgG and IgG anti-dsDNA were similar to those in wild-type mice. Despite their paucity of B cells, NZM.Br3-/- mice had an increased number of T cells, and the numbers of plasma cells and levels of IgG anti-dsDNA were similar to those in wild-type mice. Serum levels of BAFF were increased in NZM.Taci-/- and NZM.Br3-/- mice but were decreased in NZM.Bcma-/- mice. Despite their phenotypic differences, NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice had renal immunopathology and clinical disease that were at least as severe as that in wild-type mice. Conclusion Any single BAFF receptor, including BR3, is dispensable for the development of SLE in NZM mice. Development of disease in NZM.Br3-/- mice demonstrates that BAFF-BCMA and/or BAFF-TACI interactions contribute to SLE, and that a profound, life-long reduction in the numbers of B cells does not guarantee protection against SLE.

AB - Objective To determine the necessity for any individual BAFF receptor in the development of systemic lupus erythematosus (SLE). Methods Bcma-, Taci-, and Br3-null mutations were introgressed into NZM 2328 mice. NZM.Bcma -/-, NZM.Taci-/-, and NZM.Br3-/- mice were evaluated for lymphocyte phenotype and BAFF receptor expression by flow cytometry; for B cell responsiveness to BAFF by in vitro culture; for serum levels of BAFF and total IgG and IgG anti-double-stranded DNA (anti-dsDNA) by enzyme-linked immunosorbent assay; for renal immunopathology by immunofluorescence and histopathology; and for clinical disease. Results BCMA, TACI, and B lymphocyte stimulator receptor 3 (BR3) were not surface-expressed in NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice, respectively. Transitional and follicular B cells from NZM.Br3-/- mice were much less responsive to BAFF than were the corresponding cells from wild-type, NZM.Bcma-/-, or NZM.Taci-/- mice. In comparison with wild-type mice, NZM.Bcma-/- and NZM.Taci-/- mice harbored an increased number of spleen B cells, T cells, and plasma cells, whereas serum levels of total IgG and IgG anti-dsDNA were similar to those in wild-type mice. Despite their paucity of B cells, NZM.Br3-/- mice had an increased number of T cells, and the numbers of plasma cells and levels of IgG anti-dsDNA were similar to those in wild-type mice. Serum levels of BAFF were increased in NZM.Taci-/- and NZM.Br3-/- mice but were decreased in NZM.Bcma-/- mice. Despite their phenotypic differences, NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice had renal immunopathology and clinical disease that were at least as severe as that in wild-type mice. Conclusion Any single BAFF receptor, including BR3, is dispensable for the development of SLE in NZM mice. Development of disease in NZM.Br3-/- mice demonstrates that BAFF-BCMA and/or BAFF-TACI interactions contribute to SLE, and that a profound, life-long reduction in the numbers of B cells does not guarantee protection against SLE.

UR - http://www.scopus.com/inward/record.url?scp=84875734465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875734465&partnerID=8YFLogxK

U2 - 10.1002/art.37846

DO - 10.1002/art.37846

M3 - Article

C2 - 23334904

AN - SCOPUS:84875734465

VL - 65

SP - 1043

EP - 1054

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -